A feasible Study on the measurement of blood levels of anti-cancer drugs

A feasible Study on the measurement of blood levels of anti-cancer drugs - A feasible Study on the measurement of blood levels of anti-cancer drugs

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049429

Enrollment

Registered

2022-11-04

Start date

2022-03-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (i)The patient is scheduled to be treated or is being treated with the anti-cancer drugs at the National Cancer Center Hospital. ex. Axitinib, abemaciclib, ibrutinib, imatinib, osimertinib, olaparib, cabozantinib, sunitinib, pazopanib, palbociclib, brigatinib, venetoclax, regorafenib, lenvatinib, lorlatinib, etc. (ii) Adults whose written consent to the study has been obtained by the individual, or minors 16 years of age or older whose written consent to the study has been obtained by the individual and/or a surrogate

Exclusion criteria

Exclusion criteria: (1) Patients who are determined to be ineligible for this study by the principal investigator or the study office (2) Patients with active blood-borne infection (HIV, HBV, HCV, etc.) when measured by the DPS method

Design outcomes

Primary

Measure	Time frame
Assess whether measurement data by the pharmacist can be achieved within 90 minutes of specimen submission at each patient's first measurement of blood levels of antineoplastic drugs.	—

Countries

Japan

Contacts

Public ContactYuki Katsuya

National Cancer Center Hospital Department of experimental development

ykatsuya@ncc.go.jp0335422511

Outcome results